Methods for preventing and treating motor related neurological conditions
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11191478-B2
Publication Date
2021-12-07
Expiration Date
Abstract
Methods for preventing or treating motor-related neurological conditions include using ocular light therapy in connection with a conventional therapy for a motor-related neurological condition, such as a drug regimen, to adjust levels of melatonin and/or dopamine in the body of a subject. The ocular light therapy may include elevated levels of blue-green light or green light (e.g., light within a wavelength range of 460 nm to 570 nm, 490 nm to 570 nm, about 520 nm to 570 nm, etc.). The ocular light therapy may also include reduced levels of amber, orange and/or red light. Methods for diagnosing motor-related neurological conditions include ocular administration of increased amounts of amber, orange and/or red light to cause a subject to temporarily exhibit one or more symptoms of any motor-related neurological condition to which the subject is predisposed, or which the subject may already be experiencing.
Core Innovation
The invention provides a method for addressing a motor-related neurological condition experienced by a subject by administering a course of ocular light therapy to at least one eye to reduce at least one symptom. The method uses simultaneously applied spectral light conditions in which above ambient peaks of light exceed corresponding ambient light intensities in defined blue-to-blue-green and green wavelength ranges, and below ambient or no light in a higher-wavelength range greater than 570 nm to 750 nm.
The disclosed approach centers on delivering above-ambient light peaks in a first band of about 460 nm to about 520 nm and a second band of more than 520 nm to less than 540 nm. In parallel, the method administers below ambient or no light in the wavelength range of more than 570 nm to 750 nm, and in additional embodiments the ocular light therapy is administered in the evening for a duration sufficient to stimulate a dopaminergic response to reduce symptoms.
The invention also addresses circadian effects by administering the course of ocular light therapy in the evening without adversely affecting the subject’s circadian rhythms. The disclosed framework further coordinates ocular light therapy with drug therapy through time-coordinated prescribing and administration schedules, including administering drug therapy before the evening.
The disclosed subject matter includes target conditions associated with motor-related neurological conditions, and the light therapy is described as reducing symptoms including dyskinesia and various secondary symptoms. The document further reports claimed outcomes such as symptom improvements, slowed or halted progression, and reduced dyskinesia, along with long-term drug-dose stability.
Claims Coverage
The independent claims identified are clm-00001, clm-00015, and clm-00021. Across these independent claims, the coverage is built around ocular light therapy delivered in defined blue/green above-ambient spectral peaks while administering below-ambient or no light at longer wavelengths, with independent embodiments that specify evening delivery, symptom reduction, dopaminergic response stimulation, and circadian-safety limitations.
Above-ambient blue/green peaks with below-ambient or no long-wavelength light
Administering a course of ocular light therapy including simultaneously administering above ambient peaks of light having intensities that exceed intensities of corresponding peaks of ambient light in ranges: a first above ambient peak of light in a blue-to-blue-green range of wavelengths of about 460 nm to about 520 nm and a second above ambient peak of light in a green range of wavelengths of above 520 nm to less than 540 nm; and below ambient or no light in a range of wavelengths of more than 570 nm to 750 nm.
Evening ocular light therapy for symptom reduction
Administering a course of ocular light therapy to the subject in the evening for a duration of about thirty minutes or about one hour to reduce at least one symptom of the motor-related neurological condition, including simultaneously administering above ambient peaks in the blue-to-blue-green and green ranges and below-ambient or no light in the range of wavelengths of more than 570 nm to 750 nm.
Dopaminergic response stimulation with circadian-safety limitation
Administering, in the evening, a course of ocular light therapy for a duration sufficient to stimulate a dopaminergic response in the subject to reduce symptoms of the motor-related neurological condition without adversely affecting the subject's circadian rhythms, including simultaneously administering above ambient peaks in the blue-to-blue-green and green ranges and below ambient or no light in the range of wavelengths of more than 570 nm to 750 nm.
The independent claims collectively cover ocular light therapy using a specified above-ambient spectral strategy (blue-to-blue-green and green peaks) combined with below-ambient or no light at longer wavelengths (>570 nm to 750 nm), with further independent limitations that require evening administration and, in one independent claim, a duration sufficient to stimulate a dopaminergic response without adversely affecting circadian rhythms.
Stated Advantages
Reduces at least one symptom of a motor-related neurological condition.
Stimulates a dopaminergic response.
Reduces symptoms without adversely affecting the subject’s circadian rhythms.
Provides claimed improvement outcomes, including symptom improvements and reduced dyskinesia.
Claims slowed or halted progression and long-term drug-dose stability.
Documented Applications
Preventing or treating motor-related neurological conditions (movement disorders) via ocular light therapy.
Reducing symptoms associated with Parkinson's disease, dyskinesia, and a range of secondary symptoms.
Early diagnosis using ocular exposure to amber/orange/red light to temporarily exacerbate symptoms.
Reducing a range of additional neurodegenerative, psychiatric, and sleep-related conditions explicitly enumerated in dependent claim context, including Alzheimer’s disease and various dementia, anxiety and mood disorders, and insomnia disorders.
Interested in licensing this patent?